effectiveness and complications of 188re-hedp in palliative treatment of diffuse skeletal metastases

Authors

davood beiki

maryam tajik

peiman haddad

babak fallahi

amir mohammad arefpour

abstract

introduction: bone metastases are the most common cause of cancer-related pain in various primary malignant tumors, most often, breast and prostate. 188re-hydroxyethylidene diphosphonate (188re-hedp) is a new and less expensive bone seeking radiopharmaceutical with favorable physical characteristics of the radionuclide such as short half life of 16.9h, maximal β energy of 2.1 mev with a 15% γ-component of 155 kev and easily available from an in-house 188w/188re generator. the aim of this study is to evaluate the therapeutic efficacy and safety profile of bone palliative therapy following administration of 188re-hedp. methods: twenty patients with painful metastatic bone lesions secondary to breast, prostate, multiple myeloma, ampulla of vater and lung cancers received 1 mci/kg of 188re-hedp. four hours after treatment, post-therapy scintigraphy was performed. all patients were interviewed using a standard set of questions (visual analogue scale: vas) concerning their pain relief before, and after therapy at weekly intervals for the first month and every 2 weeks for the following 4 months. the general condition of the patients was also evaluated by karnofsky-index and ecog (eastern cooperative oncology group) performance status. hematologic profiles were recorded before treatment and every two weeks up to 8 weeks after treatment. results: overall pain relief was found in 68.8% of patients. decreased from 8.37±2.12 to 5.68±2.98 at vas was observed 4 weeks after treatment. the osteoblastic lesions (breast and prostate) showed rather similar response to the treatment. mean platelet counts decreased in 6th week and returned to baseline level in 8th week. one patient showed grade iii leukopenia without any serious complication. conclusion: 188re-hedp is an effective radiopharmaceutical for metastatic bone pain palliation therapy. side effects include mild and transient thrombocytopenia and leucopenia and no life threatening side effect is observed.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Effectiveness and complications of 188Re-HEDP in palliative treatment of diffuse skeletal metastases

Introduction: Bone metastases are the most common cause of cancer-related pain in various primary malignant tumors, most often, breast and prostate. 188Re-hydroxyethylidene diphosphonate (188Re-HEDP) is a new and less expensive bone seeking radiopharmaceutical with favorable physical characteristics of the radionuclide such as short half life of 16.9h, maximal β energy of ...

full text

Effectiveness and complications of 153Sm-EDTMP in palliative treatment of diffuse skeletal metastases

Introduction: The aim of the present study was to evaluate the efficacy and safety profile of bone palliative therapy following administration of 153Sm-EDTMP in patients with intractable metastatic bone pain. Methods: Sixteen patients (9 male, 7 female) aged 29-80 years (57.3±16.7 years) with severe metastasis-related bone pain resistant to analgesic medications were enrolled in the...

full text

effectiveness and complications of 153sm-edtmp in palliative treatment of diffuse skeletal metastases

introduction: the aim of the present study was to evaluate the efficacy and safety profile of bone palliative therapy following administration of 153sm-edtmp in patients with intractable metastatic bone pain. methods: sixteen patients (9 male, 7 female) aged 29-80 years (57.3±16.7 years) with severe metastasis-related bone pain resistant to analgesic medications were enrolled in the study. all...

full text

Preparation and biological evaluation of 186/188Re-HEDP as a new cocktail radiopharmaceutical for palliative treatment of osseous metastases in wild type rat

Introduction: The palliative care in patients with bone metastasis includes variety of techniques such as conventional analgesics, surgery, external beam radiotherapy, hormone therapy, chemotherapy and using bone-seeking radiopharmaceuticals. Even some of the recent works used combined methods like chemotherapy and radionuclide therapy or using radionuclide therapy as adjuvant ...

full text

My Resources

Save resource for easier access later


Journal title:
iranian journal of nuclear medicine

Publisher: tehran university of medical sciences

ISSN 1681-2824

volume 23

issue 1 2014

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023